We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Renal Nerve Ablation in Chronic Kidney Disease Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01442883
Recruitment Status : Recruiting
First Posted : September 29, 2011
Last Update Posted : January 12, 2018
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:

In patients with treatment resistent hypertension renal nerve ablation emerged as an effective interventional approach of treating hypertensive disease with a progressively increasing fall in blood pressure. Decreased activity of the sympathetic nervous system is one of the major underlying pathogenetic mechanism of the fall in blood pressure but the precise mechanisms that causes the fall in blood pressure in the short-term and, in particular, long-term remains elusive. The objective of the study is to understand the pathogenetic mechanisms of renal denervation beyond the reduced activity of the sympathetic nervous system. In 100 hypertensive patients most advanced technology will be applied, before and repeatedly after renal denervation, throughout the follow-up period of 1 year. Systemic activity of the renin angiotensin aldosterone system, renal perfusion (by MRI spin labelling technique), local activity of the renin angiotensin system in the kidney (urinary angiotensinogen concentrations), sodium excretion and total sodium content (23 Na-MRI technique) and vascular remodelling of small (retinal arterioles 50 - 150 µm) and large arteries (carotid - femoral pulse wave velocity and augmentation index, both measured over 24 hours) will be assessed. Identification of the pathogenetic mechanisms involved in the fall in blood pressure after renal denervation may help to identify those hypertensive patients that profit most from renal nerve ablation in terms of blood pressure reduction.

The investigators propose the following hypotheses why a progressive decrease in blood pressure happens, in addition to the decreased activity of the central nervous system, after renal nerve ablation:

Short term effects:

A)Preservation of renal function and perfusion B)Reduction of local RAS activity in the kidney C)Exaggerated sodium excretion immediately after renal nerve ablation

Long term effects:

D)Decrease of total sodium content after 6 and 12 months. E)Improvement of vascular wall properties after 6 and 12 months


Condition or disease Intervention/treatment
Hypertension Chronic Kidney Disease Device: Simplicity Catheter

Detailed Description:
In patients with treatment resistent hypertension renal nerve ablation emerged as an effective interventional approach of treating hypertensive disease with a progressively increasing fall in blood pressure. Decreased activity of the sympathetic nervous system is one of the major underlying pathogenetic mechanism of the fall in blood pressure but the precise mechanisms that causes the fall in blood pressure in the short-term and, in particular, long-term remains elusive. The objective of the study is to understand the pathogenetic mechanisms of renal denervation beyond the reduced activity of the sympathetic nervous system. In 100 hypertensive patients most advanced technology will be applied, before and repeatedly after renal denervation, throughout the follow-up period of 1 year. Systemic activity of the renin angiotensin aldosterone system, renal perfusion (by MRI spin labelling technique), local activity of the renin angiotensin system in the kidney (urinary angiotensinogen concentrations), sodium excretion and total sodium content (23 Na-MRI technique) and vascular remodelling of small (retinal arterioles 50 - 150 µm) and large arteries (carotid - femoral pulse wave velocity and augmentation index, both measured over 24 hours) will be assessed. Identification of the pathogenetic mechanisms involved in the fall in blood pressure after renal denervation may help to identify those hypertensive patients that profit most from renal nerve ablation in terms of blood pressure reduction.

Study Design

Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Understanding the Mechanisms of Progressive Decrease in Blood Pressure After Renal Nerve Ablation
Study Start Date : November 2010
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : June 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Kidney Diseases
U.S. FDA Resources

Groups and Cohorts

Group/Cohort Intervention/treatment
treatment resistant hypertensives with CKD 3-5 Device: Simplicity Catheter
percutaneous selective renal sympathetic nerve ablation with the use of the Simplicity Catheter system


Outcome Measures

Primary Outcome Measures :
  1. office BP [ Time Frame: baseline, 6 months ]
    Change in office blood pressure from baseline to 6 months post-renal nerve ablation

  2. 24-h ABPM [ Time Frame: baseline, 6 months ]
    Change in 24 hour ambulatory blood pressure (ABPM) from baseline to 6 months post-renal nerve ablation

  3. Magnetic resonance imaging (MRI) [ Time Frame: baseline, 6 months ]
    • change in total sodium content measured by MRI from baseline to 6 months post-renal nerve ablation
    • change in renal perfusion measured by MRI spin labelling technique from baseline to 6 months post-renal nerve ablation

  4. Albuminuria [ Time Frame: baseline, 6 months ]
    Change in urinary albumin/creatinine ratio from baseline to 6 months post renal nerve ablation (spot urine)

  5. local RAS activity [ Time Frame: baseline, 6 months ]
    Change in urinary angiotensinogen concentration from the morning spot urine from baseline to 6 months post-renal nerve ablation

  6. systemic RAS activity [ Time Frame: baseline, 6 months ]
    • change in sodium, potassium and creatinine from baseline to 6 months post-renal nerve ablation
    • change in aldosterone excretion from baseline to 6 months post-renal nerve ablation
    • change in sodium / potassium ratio from baseline to 6 months post-renal nerve ablation
    • change in plasma renin activity and angiotensin II concentration at least 30 minutes of rest in a supine position and immediately after standing from baseline to 6 months post-renal nerve ablation

  7. vascular structure and function of large and small arteries [ Time Frame: baseline, 6 months ]
    • change in flow-mediated vasodilation (FMD) from baseline to 6 months post-renal nerve ablation
    • change in scanning laser Doppler flowmetry (SLDF) from baseline to 6 months post-renal nerve ablation
    • change in pulse wave analysis (PWA) from baseline to 6 months post-renal nerve ablation
    • change in pulse wave velocity from (PWV) baseline to 6 months post-renal nerve ablation
    • change in urinary albumine creatinine ratio (UACR) of the morning spot urine sample from baseline to 6 months post-renal nerve ablation


Secondary Outcome Measures :
  1. BP [ Time Frame: 1 and 12 months ]
    • change in office blood pressure from baseline to 1 and 12 months post-renal nerve ablation
    • change in 24 hour ambulatory blood pressure from baseline to 1 and 12 months post-renal nerve ablation

  2. local RAS activity [ Time Frame: 1 day and 1 months ]
    Change in urinary angiotensinogen concentration from the morning spot urine from baseline to 1 day and 1 months post-renal nerve ablation

  3. systemic RAS activity [ Time Frame: 1 day and 1 months ]
    • change in sodium, potassium and creatinine from baseline to 1 day and 1 months post-renal nerve ablation
    • change in albuminuria from baseline to 1 and 12 months post-renal nerve ablation
    • change in aldosterone excretion from baseline to 1 day and 1 months post-renal nerve ablation
    • change in sodium / potassium ratio from baseline to 1 day and 1 months post-renal nerve ablation
    • change in plasma renin activity and angiotensin II concentration at least 30 minutes of rest in a supine position and immediately after standing from baseline to 1 day and 1 months post-renal nerve ablation

  4. vascular structure and function of large and small arteries [ Time Frame: 12 months ]
    • change in flow-mediated vasodilation (FMD) from baseline to 12 months post-renal nerve ablation
    • change in scanning laser Doppler flowmetry (SLDF) from baseline to 12 months post-renal nerve ablation
    • change in pulse wave analysis (PWA) from baseline to 12 months post-renal nerve ablation
    • change in pulse wave velocity from (PWV) baseline to 12 months post-renal nerve ablation
    • change in urinary albumine creatinine ratio (UACR) of the morning spot urine sample from baseline to 12 months post-renal nerve ablation

  5. MRI [ Time Frame: 1 day, 1 and 12 months ]
    • change in total sodium content measured by MRI from baseline to 12 months post-renal nerve ablation
    • change in renal perfusion measured by MRI spin labelling technique from baseline to 1 day and 1 months post-renal nerve ablation


Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
treatment resistant hypertensive adults with chronic kidney disease 3 - 5
Criteria

Inclusion Criteria:

  • treatment resistant hypertension
  • chronic kidney disease 3 - 5
  • male of female aged over 18 years
  • written informed consent
  • agreement to attend all study visits as planned in the protocol

Exclusion Criteria:

  • any contraindications for MRI
  • claustrophobia
  • strabismus
  • severe ocular diseases
  • history of epilepsia
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01442883


Contacts
Contact: Christian Ott, MD +49-9131-85 ext 36245 christian.ott@uk-erlangen.de

Locations
Germany
Clinical Research Unit, Department of Nephrology and Hypertension, University of Erlangen-Nürnberg Recruiting
Erlangen, Germany, 91054
Contact: Christian Ott, MD    +49-9131-85 ext 36245    christian.ott@uk-erlangen.de   
Sub-Investigator: Christian Ott, MD         
Joachim Weil Active, not recruiting
Lübeck, Germany
Sponsors and Collaborators
University of Erlangen-Nürnberg Medical School
Investigators
Principal Investigator: Roland E Schmieder, MD University of Erlangen-Nürnberg, Germany
More Information

Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: University of Erlangen-Nürnberg Medical School
ClinicalTrials.gov Identifier: NCT01442883     History of Changes
Other Study ID Numbers: RNA-CKD3-5
First Posted: September 29, 2011    Key Record Dates
Last Update Posted: January 12, 2018
Last Verified: March 2017

Keywords provided by University of Erlangen-Nürnberg Medical School:
Treatment Resistant

Additional relevant MeSH terms:
Kidney Diseases
Renal Insufficiency, Chronic
Urologic Diseases
Renal Insufficiency